Evidence map›Paper›PMID 32019558›Full record

ArticleDiagnostic pathology2020

The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt.

Osama Mohamed, Ahmed El Bastawisy, Nasr Allahlobi, Mona S Abdellateif, Abdel Rahman N Zekri, Sabry Shaarawy, Zeinab Korany, Marwa Mohanad, Abeer A Bahnassy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Osama MohamedDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Ahmed El BastawisyDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Nasr AllahlobiDepartment of Medical Oncology, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Mona S AbdellateifMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Abdel Rahman N ZekriMolecular Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Sabry ShaarawyMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Zeinab KoranyMedical Biochemistry and molecular biology, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt.
Marwa MohanadBiochemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th October, Cairo, 12945, Egypt.
Abeer A BahnassyPathology Department, National Cancer Institute, Cairo University, Cairo, 11976, Egypt. chaya2000@hotmail.com.
Cairo University · EGMisr University for Science and Technology · EG

Funding

NCI, Cairo university 153-17
6 · The paper itself

Abstract

backgroundCD68+ tumor-associated macrophages (TAM) play an important role in the progression of classical Hodgkin lymphoma (cHL). We assessed the role of CD20 and CD68 + TAM in a cohort of cHL patients from Egypt and correlated the number of CD68 + cells with patients' characteristics, response to treatment, overall and progression free survival rates (OS & PFS).

methodsCD20 expression and CD68 + TAM numbers were assessed in representative tumor tissues obtained from 81 cHL patients using flowcytometry (FCM), immunohistochemistry (IHC), and Rt-PCR techniques.

resultsThe expression levels of CD68 protein by IHC was high in 27 (33.3%), moderate in 15 (18.5%), low in 15 (18.5%), and negative in 24 (29.6%) patients (p = 0.13). CD68-mRNA expression was high in 43/81(53.1%), and low in 38(46.9%) patients (p = 0.6). The number of CD68 + TAM (by FCM) was low (< 20 cells) in 42/81 (51.9%), and high (≥20 cells) in 39/81 (48.1%) patients (p = 0.74). CD68 expression (by FCM, IHC& Rt-PCR) associated significantly with poor response to treatment, decreased CD20 expression, reduced OS and PFS rates (p < 0.001 for all). CD68 expression (by Rt-PCR only) associated significantly with advanced disease stage (p = 0.04). The age of the patients, high CD20 expression & high CD68+ macrophage number were independent prognostic factors for OS (p= 0.02, p = 0.008 & p = 0.009; respectively). However, the age of the patient, high CD20, and high CD68+ macrophage expression (by FCM&IHC) were independent prognostic factors for DFS (p. = 0.004, p. = 0.01, p. = 0.007 and p. = 0.01; respectively).

conclusionCD68 + TAM expression (by Rt-PCR, FCM and/or IHC) can identify patients with poor response to treatment and reduced survival rates (OS& PFS). Assessment of CD68 + positive macrophages by FCM is superior to other methods (Rt-PCR and IHC) as a prognostic factor for DFS and OS rates.

Indexed as

AdolescentAdultAntigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticCD68 MoleculeCohort StudiesEgyptFemaleHodgkin DiseaseHumansImmunohistochemistryMacrophagesMaleMiddle AgedNeoplasm StagingAntigens, CDAntigens, CD20Antigens, Differentiation, MyelomonocyticCD68 antigen, humanCD68 MoleculeCD20CD68cHLPrognosisSurvivalTAM

Identifiers

PMID32019558
PMCPMC7001371
OpenAlexW3008393936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.